Alpha 2.0
Login Register
» Authors » Baha Sharaf

Baha Sharaf

Explore the profile of Baha Sharaf including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 58
Followers 0
Related Specialties
Oncology
General Medicine
Science
Top 10 Co-Authors
Hikmat Abdel-Razeq
Faris Tamimi
Hira Bani Hani
Osama Salama
Rayan Bater
Sarah Edaily
Mais Alkyam
Samer Salah
Brandie Heald
Ramiz Abu-Hijlih
Published In
Cancers (Basel)
Sci Rep
World J Oncol
Breast Cancer (Dove Med Press)
Front Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Dual Anti-HER2 Therapy Vs Trastuzumab Alone with Neoadjuvant Anthracycline and Taxane in HER2-Positive Early-Stage Breast Cancer: Real-World Insights
Sharaf B, Tamimi F, Al-Abdallat H, Khater S, Salama O, Zayed A, et al.
Biologics . 2025 Mar; 19:59-71. PMID: 40066239
Introduction: The integration of anti-HER2 targeted therapy with chemotherapy has demonstrated an increase in pathologic complete response rates (pCR) in patients with HER2-positive early-stage breast cancer (EBC). This study presents...
2.
Establishment of a clinical cancer genetics program for breast cancer in a resource-limited country; challenges and opportunities
Abdel-Razeq H, Sharaf B, Tamimi F, Bani Hani H, Alsmadi O, Khalil H, et al.
Front Oncol . 2024 Nov; 14:1431985. PMID: 39507757
Breast cancer is the most common cancer among women worldwide, and its incidence rate is still increasing, especially among younger women. Nationally, it constitutes one-fifth of all cancer cases and...
3.
Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country
Abdel-Razeq H, Sharaf B, Khater S, Baidoun H, Bani Hani H, Taqash A, et al.
Immunotargets Ther . 2024 Oct; 13:501-512. PMID: 39364228
Background: Cyclin-dependent kinase (CDK) 4/6 inhibitors have revolutionized the treatment landscape of hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2 -) metastatic breast cancer (MBC). Here, we...
4.
Patterns and Frequency of Pathogenic Germline Variants Among Prostate Cancer Patients Utilizing Multi-Gene Panel Genetic Testing
Abu Hijlih R, Sharaf B, Salah S, Bani Hani H, Nielsen S, Heald B, et al.
World J Oncol . 2024 Sep; 15(5):801-808. PMID: 39328335
Background: Germline genetic testing (GGT) has significant implications in the management of patients with prostate cancer (PCa). Herein, we report on patterns and frequency of pathogenic/likely pathogenic germline variants (P/LPGVs)...
5.
Multi-Gene Panel Testing for Hereditary Cancer Predisposition Among Patients Sixty-Five Years and Above Diagnosed With Breast Cancer
Abdel-Razeq H, Tamimi F, Sharaf B, Nielsen S, Heald B, Hatchell K, et al.
World J Oncol . 2024 Sep; 15(5):777-783. PMID: 39328331
Background: The availability and affordability of germline genetic testing (GGT) has resulted in a broader utilization in daily clinical practice. However, adherence to testing guidelines is low, especially among older...
6.
Patterns and Frequency of Pathogenic Germline Mutations among Patients with Newly-Diagnosed Endometrial Cancer: The Jordanian Exploratory Cancer Genetics (Jo-ECAG) Endometrial Study
Abdel-Razeq H, Bani Hani H, Sharaf B, Tamimi F, Khalil H, Abu Sheikha A, et al.
Cancers (Basel) . 2024 Jul; 16(14). PMID: 39061183
Most of endometrial cancers are sporadic, with 5% or less being attributed to inherited pathogenic germline mutations and mostly related to the Lynch syndrome. To our knowledge, this is the...
7.
From Despair to Hope: First Arabic Experience of Lu-PSMA and Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer
Al-Ibraheem A, Abdlkadir A, Sweedat D, Maus S, Al-Rasheed U, Salah S, et al.
Cancers (Basel) . 2024 Jun; 16(11). PMID: 38893095
The objective of this retrospective study is to assess the effectiveness and safety of two beta-emitting prostate-specific membrane antigen (PSMA) radioligands, [Lu]Lu and [161Tb]Tb, in heavily treated patients with metastatic...
8.
Implementation of Universal Pan-Cancer Germline Genetic Testing in an Arab Population: The Jordanian Exploratory Cancer Genetics Study
Abdel-Razeq H, Sharaf B, Bani Hani H, Abu Hijlih R, Alkyam M, Al-Azzam K, et al.
JCO Glob Oncol . 2024 Jun; 10:e2400068. PMID: 38843472
Purpose: Germline genetic testing (GGT) significantly affects cancer care. While universal testing has been studied in Western societies, less is known about adoption elsewhere. Materials And Methods: In this study,...
9.
Genetic counseling and genetic testing for pathogenic germline mutations among high-risk patients previously diagnosed with breast cancer: a traceback approach
Abdel-Razeq H, Tamimi F, Iweir S, Sharaf B, Abdel-Razeq S, Salama O, et al.
Sci Rep . 2024 Jun; 14(1):12820. PMID: 38834641
Genetic counseling and testing are more accessible than ever due to reduced costs, expanding indications and public awareness. Nonetheless, many patients missed the opportunity of genetic counseling and testing due...
10.
Next generation selective estrogen receptor degraders in postmenopausal women with advanced-stage hormone receptors-positive, HER2-negative breast cancer
Sharaf B, Hajahjeh A, Bani Hani H, Abdel-Razeq H
Front Oncol . 2024 May; 14:1385577. PMID: 38800404
Breast cancer is the most prevalent malignancy in women, and is characterized by its heterogeneity; exhibiting various subgroups identifiable through molecular biomarkers that also serve as predictive indicators. More than...